New hope for young hodgkin patients: drug combo aims to cut radiation
NCT ID NCT06563245
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is testing a drug called brentuximab vedotin, combined with chemotherapy, for children, adolescents, and young adults newly diagnosed with classical Hodgkin lymphoma. The goal is to see if this approach can achieve a faster and more complete response, allowing fewer patients to need radiation therapy. About 96 participants will be enrolled, and the study will track how well the cancer responds and overall survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- brentuximab vedotin
- What this could lead to
- If successful, this could offer a more effective treatment for Hodgkin lymphoma in young people, reducing the need for radiation therapy and its long-term side effects.
- What could go wrong
- This is an early-phase study with only 96 participants, so results may not apply to everyone. The drug combination may cause side effects, and it's not yet proven to be better than standard care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADOLESCENT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shanghai Children's Medical Center
RECRUITINGShanghai, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug outperform standard care for a rare liver disease in teens?
- Could a trip to the pediatrician help teens beat opioid addiction?
- Drawing, stories, or toy masks: a trial tests whether fun can tame kids' fear of nebulizer treatment
- Could a COVID-19 shot boost cancer immunotherapy? a massive study digs into the timing.
- Can a new nucleotide analogue boost cancer treatment?
- Sleep hormone melatonin put to the test against lupus fatigue and inflammation